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Abstract 
Impulse control behaviours (ICBs) are a range of behaviours linked by their reward-based, 
repetitive natures. They can be precipitated in Parkinson’s Disease (PD) by dopamine 
replacement therapy, often with detrimental consequences for patients and caregivers. 
While now a well-recognised non-motor feature of treated PD, much remains unknown about 
the influence of risk factors, pathophysiological mechanisms, vulnerability factors for specific 
types of behaviour, and the optimal management strategies. Imaging studies have identified 
structural and functional changes in striatal and prefrontal brain regions, amongst others. 
Gene association studies indicate a role for genetic predisposition to PD-ICB. Clinical 
observational studies have identified potential modifiable and non-modifiable risk factors. 
Psychological studies shed light on the neurocognitive domains implicated in PD-ICBs and 
identify psychosocial determinants that may perpetuate the cycle of impulsive and harm-
avoidance behaviours. Based on these results, a range of pharmacological and non-
pharmacological management strategies have been trialled in PD-ICBs with varying success. 
The purpose of this review is to update clinicians on the evidence around the pathophysiology 
of PD-ICB. We aim to translate our findings into an interpretable biopsychosocial model which 
can be applied to the clinical assessment and management of individual cases of PD-ICB. 
 
  
Main text 
Introduction 
Impulse Control Behaviours (ICBs) are a spectrum of behaviours characterised by repetitive, 
reward-based actions and subjective loss of control. In their severe form they are known as 
Impulse Control Disorders (ICDs). In Parkinson’s disease (PD), ICBs can occur as adverse effects 
of dopamine replacement therapies (DRT), particularly dopamine agonists (DAs)1, with 
potentially devastating and long-lasting psychosocial effects on patients and caregivers2. 
There is a strong clinical need to understand the pathophysiology underlying PD-ICB and how 
to evaluate and manage PD-ICBs in clinical practice. 
PD-ICBs are common, although the reported prevalence varies widely (14-40%) 1 3-6. This is 
likely due to differences in diagnostic criteria, assessment tools7 and possibly cultural 
differences between populations3 6. 
The most common PD-ICBs described are: 
• Pathological gambling (PG)S1 
• Hypersexuality8 
• Compulsive shopping (CS)S2 
• Compulsive or binge eating (BE)S1 
• Hobbyism9 10 
• Punding9 
• Dopamine dysregulation syndrome (DDS)/compulsive medication use11 
Other behaviours, sometimes considered subsets of those above, include hoarding12 and 
walkabout13. ICBs more specific to the technological era, such as internet-overuse and 
gamingS3 are increasingly recognised. This is unsurprising, as a fundamental nature of these 
technologies is to encourage repetitive use leading to an increased recognition of excessive 
use as a problem in the wider population14. The specific form of internet-overuse varies, and, 
depending on the driver may include aspects of hobbyism, punding or even gambling and 
hypersexuality. The incidence of these behaviours is likely to increase with time as technology 
is increasingly used by older generations. 
A phenomenon that specialists may recognise from clinical practice is that PD-ICBs exists on 
a broad spectrum of severity, ranging from a change in premorbid traits that are still 
considered within the limits of normal behaviour to severe disorders of high frequency and 
intensity (see Figure 1). 
Diagnostic Statistical Manual (DSM-) and DSM-aligned diagnostic criteria exist for individual 
ICBs (see references listed above). While this specificity is useful in research, these criteria 
risk giving the erroneous impression that PD-ICBs exist as a binary entity - in which patients 
either meet or do not meet criteria for ‘caseness’. Conversely, screening questionnaires such 
as the Questionnaire for Impulse Control Disorders in Parkinson’s Disease (QUIP)13 and the 
Minnesota Impulsive Disorders Interview (MIDI)15 may capture most cases without 
differentiating the innocuous from the dangerous. This categorical approach fails to recognise 
the dimensional nature of the spectrum where ‘subsyndromal’ PD-ICDs may have an 
observable impact on patients without meeting strict diagnostic criteria. This has additionally 
been a limitation of many PD-ICB prevalence studies1 7. Attempts to address this dimensional 
approach include the QUIP Rating Scale (QUIP-RS) and Parkinson’s Impulse Control Scale 
(PICS)16 17. Recognition of PD-ICB as a spectrum will help to risk-stratify patients, target 
interventions appropriately and assess response to such interventions in future observational 
and treatment studies. 
The objectives of this review are to: 
1. Update clinicians on what is known about the pathophysiology of PD-ICB, presenting 
a comprehensive and interpretable biopsychosocial model that takes into account 
neurochemical, neural-network, psychological and epidemiological evidence to date. 
2. Highlight how to assess and manage PD-ICBs using pharmacological and non-
pharmacological approaches, underpinned through application of this model. 
Terminology regarding PD-ICBs differs between studies and specialist centres. For example, 
the term ‘impulsive and compulsive behaviours’18 is also used. While harm-avoidance is 
included in the psychological formulation of PD-ICB, there is little evidence to suggest the 
behaviours denote ‘compulsions’, which are defined as behaviours specifically targeted to 
relieve anxietyS1. Furthermore, the strongest evidence to date favours ICBs representing a 
‘devaluation of future rewards’ or immediate gratification (also known as myopia for the 
future)19. Therefore, in this review, the term ‘Impulse Control Behaviour’ and following 
terminology is used: 
• Impulse Control disorder (ICD/PD-ICD): An ICB that fits DSM or published DSM-aligned 
criteria. i.e. ‘Syndromal’ ICD. The cornerstone of such criteria is that the ICB 
sufficiently impacts on social and/or occupational functioning. 
• Subsyndromal Impulse Control Disorder: An ICB which falls short of the criteria for 
ICD. In the case of PD, this specifically refers to a change in behaviour; either an 
exacerbation of previous behaviours or their novel occurrence, thought related to the 
introduction of DRT. 
• ICB/PD-ICB: The full spectrum of ICB, as defined above, including not only syndromal 
ICDs but also subsyndromal ICDs. N.B. this includes the full range of disinhibitory 
psychopathologies listed above including hobbyism and punding. 
 
Pathophysiology 
Animal models, imaging, neuropsychometric and observational clinical studies provide 
evidence on mechanisms underpinning PD-ICB. Evidence from the study of ICBs in the healthy 
population, particularly PG, have been extrapolated to, and investigated in PD. While 
describing all the complex theories proposed to explain impulsivity would be beyond the 
scope of this review, we aim to examine some of the more comprehensive neurochemical, 
neural-network, psychological and clinical models of PD-ICB. 
Neurochemical modelling 
The role of dopamine 
While impulsivity is a complex and heterogenous concept (see psychological modelling 
below), reward and punishment learning, mediated primarily by dopamine, are recognised as 
key components of impulsivity in PD-ICBS4, providing a useful model to examine the role of 
dopamine in PD-ICB. 
Dopamine receptor subtypes have varying effects and patterns of distribution throughout the 
basal ganglia. D3-receptors are expressed preferentially in the ventral striatum (VS), linked to 
reward processingS5. D1 and D2 receptors have been proposed, in a computational model, to 
mediate motor response inhibition, demonstrated by procedural learning tasks20. Phasic 
dopaminergic bursts in the D1-mediated direct (excitatory, “Go”) pathway are released in 
response to positive stimuli. Dips or pauses in dopamine release in the D2-mediated indirect 
(inhibitory, “NoGo”) pathway occur in response to negative outcomes. This model has been 
consistently replicated clinically: Medicated PD patients demonstrate impaired negative-
reinforcement learning and an enhanced response to positive-reinforcement, with the 
opposite observed in unmedicated PD individuals 21 22 S6. 
Modern DAs demonstrate relative selectivity for D2-type (D2, D3, D4) receptors over D1-types 
(D1, D5)S7. DAs, therefore, may overstimulate D3-mediated reward circuits and excessively 
disinhibit the D2-mediated indirect pathway. These effects may be less pronounced with 
levodopa therapy, which demonstrates a less selective, and more physiological receptor 
activation pattern. 
In animal models of PD-ICB, pramipexole enhances delay discounting, a marker of impulsive 
decision-makingS8. D2- and D3-agonists stimulate reward seeking behaviour in rodents at 
intermediate dosesS9. However, in these experimental models, these effects also occur in 
control animals, not just PD-models. Furthermore, in the latter studyS9, D1-specific agonists 
and higher doses of D2 and D3-agonists actually induced reward aversion, inconsistent with 
the clinical models described above. It is thus likely that preclinical models cannot yet recreate 
all the complex neurochemical processes underlying PD-ICBS10. 
Nuclear imaging studies demonstrate lower levels of D2/D3 receptor binding 23-25 and reduced 
dopamine transporter (DAT) availability26 in the VS of PD-ICB subjects. The latter has been 
shown in longitudinal analyses to predate the introduction of DRT27 S11. These findings may 
be explained by greater levels of VS dopamine activity (either due to enhanced release and/or 
reduced uptake). Thus, D2/D3 receptors are ‘overdosed’ by the addition of DRT, increasing 
the potential for reward driven behaviours S12. Conversely, PD-ICB patients may have a 
greater burden of dopaminergic circuit denervation, potentially explaining why patients with 
more advanced disease are at greater risk of PD-ICB28 29.  
The role of genetics in dopamine signalling  
Kraemmer and colleagues30 found the heritability of PD-ICB to be 57%, suggesting a genetic 
predisposition in some individuals. Although only a screening questionnaire (QUIP) was used 
for diagnosis. Heterogeneity in neurotransmitter metabolism may explain why some 
individuals are at greater risk of PD-ICB. The findings of seven candidate gene association 
studies comparing PD patients with and without PD-ICB are shown in Table 1. Polymorphisms 
of DRD1, DRD2, DRD3, SLC22A1 and DDC, all involved in dopamine signalling and metabolism, 
have been associated with increased risk of PD-ICB. A polymorphism of DRD4 was associated 
with changes in gambling task performance on levodopa31. Genetic panels may be useful in 
predicting PD-ICB risk30. However, results are variable and contradictory, likely due to 
differences in diagnostic criteria, ethnicity and candidate gene selection. Large scale, multi-
centre, genome wide-analysis studies are warranted to investigate the role of genetic risk in 
PD-ICBs. 
Other neurotransmitters 
Serotonin, noradrenaline, glutamate and opioids have been implicated in addictive 
behaviours such as PG and substance use disorder (SUD). For a detailed review, see32. Genes 
involved in neurotransmitter signalling (GRIN2B; glutamate, HTR2A; serotonin and OPRK1; 
opioids) have been implicated in PD-ICB risk (see table 1). Other than these gene association 
studies however, there has been little study into the role of other neurotransmitters in PD-
ICB. Modest and sometimes conflicting results for the use of selective serotonin reuptake 
inhibitors (SSRIs)S13, selective noradrenaline reuptake inhibitors (SNRIs)S14, opioid receptor 
antagonistsS15 and N-methyl-D-aspartate (NMDA-) glutamate receptor antagonists33 S16-S18 are 
discussed in more detail under ‘management’ below. 
  
Gene Associated Not associated 
DRD3    
rs6280 Lee et al, 2009S70 
Krishnamoorthy et al, 2016S71 
Zainal Abidin et al, 2015S72 
McDonell et al, 2018S73 
Redenšek et al, 2019S74 
rs3732783  Zainal Abidin et al, 2015S72 
GRIN2B   
rs1806201  Lee et al, 2009S70 
Krishnamoorthy et al, 2016S71 
Redenšek et al, 2019S74 
rs7301328 Lee et al, 2009S70 
Zainal Abidin et al, 2015S72 
 
rs1019385  Lee et al, 2009S70 
 
SLC22A1   
rs628031 Redenšek et al, 2019S74  
   
COMT   
rs4680  Vallelunga et al, 2012S75 
Redenšek et al, 2019S74 
rs165815  Redenšek et al, 2019S74 
   
DRD1   
rs4867798 Zainal Abidin et al, 2015S72  
rs4532 Zainal Abidin et al, 2015S72  
rs265981  Zainal Abidin et al, 2015S72 
   
DRD2   
rs1800497 
(Taq1A) 
Zainal Abidin et al, 2015S72 
McDonell et al, 2018S73 
 
Lee et al, 2009S70 
Vallelunga et al, 2012S75 
Kraemmer et al, 201630 
rs1799732  Redenšek et al, 2019S74 
rs1801028  Redenšek et al, 2019S74 
rs104894220  Zainal Abidin et al, 2015S72 
rs144999500  Zainal Abidin et al, 2015S72 
rs6277  McDonell et al, 2018S73 
   
DDC   
rs3837091 Kraemmer et al, 201630 Redenšek et al, 2019S74 
rs921451  Redenšek et al, 2019S74 
rs1451375 Kraemmer et al, 201630  
   
MAOB   
rs1799836  Redenšek et al, 2019S74 
   
SLC6A3   
3ʹ UTR 40 bp 
VNTR 
 Vallelunga et al, 2012S75 
rs393795  Redenšek et al, 2019S74 
rs6347  Redenšek et al, 2019S74 
rs104209  Redenšek et al, 2019S74 
   
SLC6A4   
5-HTTLPR  Lee et al, 2009S70 
   
SLC22A1   
rs628031  Redenšek et al, 2019S74 
SLC7A5   
rs1060253  Redenšek et al, 2019S74 
rs1060257  Redenšek et al, 2019S74 
   
SLC18A2   
Rs14240  Redenšek et al, 2019S74 
   
SV2C   
rs1423099  Redenšek et al, 2019S74 
   
HT2RA   
rs6313  Krishnamoorthy et al, 2016S71 
DRD4   
rs1800443  Zainal Abidin et al, 2015S72 
   
DRD5   
rs144132215  Zainal Abidin et al, 2015S72 
   
HTR2A   
rs6313 Lee et al, 2012*S76 
Kraemmer et al, 201630 
 
   
OPRK1   
rs702764 Kraemmer et al, 201630  
   
ADRA2C   
rs76337672  Kraemmer et al, 201630 
 
Table 1. Genetic polymorphisms investigated in PD-ICB 
This table summarises the findings of 8 candidate gene association studies investigating polymorphisms 
potentially associated with PD-ICB, according to whether or not the study found and association. 
*Borderline association found across whole group (p=0.055), significant association amongst lower levodopa 
equivalent dose (LED) patients (p=0.011) 
 
  
Neural-network modelling 
Impulsivity and reward-based decision making are mediated by a complex neural-network 
interconnected by mesocortical and mesolimbic circuits. Clinical imaging studies have 
attempted to demonstrate whether anatomical and/or functional changes in neural-
networks predispose certain individuals to ICB within the general population and in PD. 
Reward circuits project from the ventral tegmental area (VTA) to cortical and sub-cortical 
areasS19. Disruption of these circuits have been implicated in ICDs such as pathological 
gambling and SUD32. The specific areas implicated vary according to imaging modalities used. 
Such studies have also been used to investigate a neural-network correlate for increased risk 
of PD-ICB. Voxel-based morphometry has identified patterns such as cortical thickening of the 
anterior cingulate cortex (ACC)S20 and cortical thinning of the orbitofrontal cortex (OFC)S21, 
associated with PD-ICBs. However, such findings are inconsistently replicated and this 
modality may not be sensitive to subtle or functional changes34. 
Brain activity studies such as functional MRI (fMRI) may be more sensitive to functional 
changes in reward circuitry. These studies are small in size, few in number, and vary in their 
methods and results. A recent meta-analysis35 of such studies found that the most 
consistently implicated brain activity changes between PD-ICB and PD-non-ICB individuals 
were: 
• Hyperactivity of the VS. VS dopamine release is triggered by unexpected reward 
stimuli, an important initial step in reward learning. An intact VS, with greater 
dopaminergic activity, may be more sensitive to the ‘overdose’ of DRTS12, as 
mentioned in ‘neurochemical modelling’. 
• Hyperactivity of the OFC. Dopaminergic activity of the OFC is thought to mediate 
reward processing and decision making in goal-directed learningS22. The OFC may be 
particularly vulnerable to the tonic stimulation of dopamine receptors by DAsS23. 
• Hypoactivity of the ACC. Reduced ACC activity may impair the perseveration and 
premeditation required to mitigate impulsive decision makingS24. 
Most imaging studies are cross-sectional and unable to infer causality in the correlations 
identified. Longitudinal studies are required to identify whether changes in reward circuitry 
represent a predisposition towards impulsivity or a response to chronic exposure to DA or 
PD-ICB itself. 
Comparison of baseline volumetric MRI in drug-naïve patients did not differentiate between 
those who later developed PD-ICB (n=42) and PD controls in a case-control study nested 
within the longitudinal Parkinson Progressive Markers Initiative (PPMI) cohortS25. However, 
another longitudinal study36 using resting-state fMRI found several differences in baseline 
connectivity that were later associated with greater risk of PD-ICB (increased salience 
network (OFC) connectivity, reduced central executive network (left supramarginal gyrus) and 
central executive network (left precuneus, right middle temporal gyrus) connectivity). 
Coupling between salience networks and central executive networks also correlated with 
greater PD-ICB severity. This study was small (n=30, 15 with PD-ICB) and relatively short in 
duration (36-month follow-up). Only resting-state fMRI was assessed, whereas fMRI during 
reward-based tasks may be more sensitive to reward-circuit changes. Nevertheless, this and 
the DAT studies discussed previously27 S11 suggest that at least some neural-network changes 
precede the introduction of DRT and onset of PD-ICB. 
Diffusion tensor imaging (DTI) studies postulate a role for white-matter denervation in 
impulsivityS26 S27. 
Larger, prospective functional imaging studies are needed to better investigate the role of 
heterogeneity in neural-networks and the clinical utility of imaging in predicting PD-ICB risk. 
 
Psychological modelling 
Increased understanding of the neuropsychology of ICBs such as PG and SUD may shed light 
on the formulation of ICB, the role of dopamine and the predilection towards ICB amongst 
certain PD patients. Here we outline psychological models of (1) reward-seeking and 
impulsivity and (2) harm-avoidance. 
Impulsivity 
Impulsivity can be divided into several, not mutually exclusive domains, according to the 
psychometric tests through which they measured37. In general, these are conceptualised as:  
1. Motor impulsivity (Response inhibition): Acting without thinking. Most commonly 
measured by Go/NoGoS28 and Start-Stop Reaction tasksS29. 
2. Decision-making impulsivity: Decision making involves several cognitive domains 
including executive function, reward processing and punishment sensitivity.  
Impulsive individuals appear to make riskier decisions, disproportionately 
incentivised by positive reward and desensitised to negative consequences. 
Measured, in part, by gambling tasksS30 S31. 
3. Choice impulsivity: Closely related to decision making; impulsive individuals have 
difficulty in delaying gratification despite greater rewards in Delay-Discounting 
tasksS32. 
4. Reflection impulsivity: Insufficient information gathering when making decisions. 
Measured by information sampling tasksS33. 
PD-ICBs can be modelled using these domains, though questions still remain regarding  their 
direct translation into pathological behaviours (see review by Dawson and collegues18). While 
the sensitivity and specificity of such tests appears valid, their role as discriminators of 
severity remains unclear. Whilst some inconsistencies may be explained by variations in 
methodology, there currently appear limitations to the real-world applicability, (or ‘ecological 
validity’)S34, of such paradigms. Such challenges are replicated in other conditions where 
executive dysfunction may pose a clinical problem and require psychometric evaluation, e.g. 
traumatic brain injuryS35.  
PD-ICB patients score higher than PD controls for motor impulsivity, non-planning (choice) 
impulsivity and attention (reflection impulsivity) on the Barratt Impulsiveness ScaleS36 and on 
the Delay-Discounting Task, specific to choice impulsivity28. As described in neurochemical 
modelling above; untreated PD patients demonstrate impaired reward learning and intact 
reversal learning, whereas dopaminergic treatment reverses this pattern21. Drug-naïve PD 
patients also demonstrate reduced novelty-seeking behaviours compared to healthy 
controls38. While this might suggest that PD patients, in the absence of DRT, are less impulsive 
than the general population, there is little evidence to indicate a difference in PD-ICB 
prevalence of between drug-naïve PD patients and healthy controls39. DAs have been shown 
to interfere with reward prediction error in PD patients. Excessive dopaminergic stimulation 
will interpret rewards as ‘better than expected’, encouraging behaviour through incentive 
sensitisation40. 
It is possible that psychological profiles differ between PD-ICBs. For instance, hypersexuality 
was associated with poorer performance than PG and BE on Stroop tests believed to 
represent inhibitory controlS37. PG and CS have been associated with greater novelty-seeking 
and CS with greater choice impulsivity than other PD-ICBs28. 
Harm-avoidance 
Impulsivity is generally seen as a novelty-seeking behaviourS38. However, it is increasingly 
recognised that actions in PD-ICB are also driven by harm-avoidance.  While often considered 
dimensional opposites, it is likely the relationship is more nuanced than this, with both 
concepts sharing a loss of inhibition and ‘lack of control’, with an inability to learn from 
adverse outcomes37.  
PD-ICB patients perform more poorly on a temporal binding task, indicating loss of ‘sense of 
agency’, also known as sense of controlS39, and demonstrate more harm-avoidance than 
healthy controls21 S40. It has been theorised that the goal of a PD-ICB is not only to seek a 
reward or ‘high’ but relieve dysphoria or a ‘low’ (e.g. feelings of guilt, shame, loneliness, low 
mood). Various models have been proposed including the idea of (hedonic) homeostatic 
dysregulation11, applicable to DDS, where evidence suggests the majority take additional 
medication in anticipatory fear of an ‘off period dysphoria’19. 
Other psychological domains have been implicated in PD-ICB with mixed evidence. For 
example, some studies have found deficits in executive functions compared to PD controls41 
S37, while others have not 42 43.  
Clinical and demographic modelling 
Numerous studies have investigated clinical and demographic risk factors for PD-ICB1 6 28 29 44 
45. Clinical modelling may identify patients in whom DA therapy should be avoided or 
modified. 
DA-use is the most significant risk factor for PD-ICB1 29. One of the largest prospective studies 
of PD-ICB to date found DA-use increased PD-ICB risk by about 50% over levodopa alone. This 
may be an underestimate considering the high baseline rate of PD-ICB in their population46. 
For a list of risk factors associated with PD-ICB see Table 2. These factors, divided into 
potentially modifiable and non-modifiable, are supported by variable levels of evidence. The 
term potentially modifiable is used as it cannot be stated with certainty that modification of 
these risk factors will result in a lower PD-ICB risk. . For example, the association between 
smoking and alcohol consumption and PD-ICB1 46 47 may represent non-modifiable tendencies 
towards addictive behaviours, as current smoking has also been associated with PD-ICBsS41. 
Depression and anxiety28 46 are considered potentially modifiable as they have readily 
available therapies. In a cognitive behavioural therapy (CBT) trial addressing PD-ICB, both 
anxiety and depressive scores improved significantly48, though the direction of any causal 
relationship between these disorders and PD-ICBs is unclear. Apathy is considered non-
modifiable since it potentially represents greater levels of mesolimbic denervationS42 and 
lacks well validated therapies. 
A meta-analysis of 15 case-control studies, including 999 PD-ICD patients and 3507 PD-non-
ICB controls, identified that DA-use, DA levodopa daily equivalent dose (LEDD), total LEDD, 
amantadine use, PD duration, younger age, male sex and smoking were associated with 
greater PD-ICB risk. Levodopa LEDD, motor symptom severity and cognition were not49. 
However, this study identified PD-ICBs using screening questionnaires rather than more 
specific in-depth interviews17. Studies using semi-structured interviews have identified 
associations with levodopa use1, levodopa LEDD28 and motor symptom severity28 29. The roles 
of age and sex are disputed by some of these studies28 29 but supported by others1. Few50 
have found an association between PD-ICBs and cognitive impairment but most exclude 
patients with dementia. Hence the results of this meta-analysis should not be considered 
definitive. 
An important finding is that PD-ICBs appear to be a DA-LEDD dependant effect49, contrasting 
with earlier evidence28 but in concordance with more recent studies51. The role of amantadine 
in PD-ICBs is controversial, as discussed later. Male sex and younger age are well described 
risk factors for ICB in the general population. 
Additional risk factors have been described. Patients with a family history of ICB appear to be 
at greater risk of PD-ICB after the initiation of DRT1 and smoking and alcohol use have been 
hypothesised to represent a greater risk amongst those with premorbid ICB traits28. 
Apathy, a non-motor feature of PD, was associated with PD-ICB in two large-scale longitudinal 
analyses29 46. This is interesting as apathy is often considered the ‘opposite’ of impulsivity and 
is modulated by dopaminergic therapiesS43 S44. It may be that dysfunction of reward circuits 
cause a susceptibility to DRT-induced PD-ICB. Alternatively, PD-ICB patients’ disinterest in 
activities outside of their addiction or behaviour may present as a ‘pseudo-apathy’. 
A correlation between PD-ICBs and motor complications of DRT has been identified in some 
studies28 29 52 but not others50. It has been proposed that PD-ICBs and dyskinesia represent 
end products of similar DRT-induced signalling processes, the former in the VS and the latter 
in the dorsal striatum53.  
Whether or not rapid eye movement (REM)-sleep behaviour disorder (RBD), considered to 
represent prodromal parkinsonism, is associated with PD-ICB, remains uncertain. A meta-
analysis including 10 studies (n=2781) found a positive association between the two54. 
However, the majority of included studies diagnosed RBD on a screening questionnaire. Of 
the three studies using gold-standard polysomnographyS45-s47, only oneS45 found an 
association between the PD-ICB and RBD. 
 
Social factors such as being unmarried1 46 and not reaching tertiary education46 have been 
associated with PD-ICB risk, albeit inconsistently29. One study found tertiary education to be 
associated with a higher PD-ICB riskS48. Social background is important in the formulation of 
addictive behaviours, particularly gambling, in the general populationS49 S50 but there has 
been little investigation of social determinants of PD-ICB. It has been theorised55, with some 
qualitative evidence29, that psychosocial stressors (e.g. social isolation) have a predisposing 
and perpetuating effect in PD-ICB, and that supportive social networks may be protective. 
Subtle differences in associated factors have been noted between PD-ICB subtypes (PG with 
older age, BE with lower rates of anxiety, hypersexuality and CS with greater levodopa 
doses)28. Though, to our knowledge, there has been little attempt to replicate such findings 
in other observational studies1 6 29 44 45. Determining risk of different PD-ICB subtypes would 
undoubtedly be useful in clinical practice but require larger sample sizes. The shift to severity 
scales may allow for greater ease of correlation analysis.   
Clinicians should bear in mind the risk-factors listed in table 2 when considering DA therapy 
in PD patients and monitoring for PD-ICB. However, it should be stressed that no risk factors 
have been associated strongly enough to be considered an absolute contraindication to DA 
and evidence remains mixed for many factors. 
 
 
  
  Non-modifiable Potentially-modifiable 
Medication-related factors  DA use* 
 Levodopa-use** 
 Medication dose 
-Total LEDD* 
-DA LEDD* 
 Other medications 
-Amantadine* 
Disease-related factors Disease duration*  
Motor severity 
-MDS-UPDRS-III** 
-MDS-UPDRS-II 
-Hoehn and Yahr** 
 
Cognitive impairment**  
Presence of RBD  
 Depression 
 Anxiety 
Apathy  
Patient factors Age*  
 Sex*  
  Smoking history* 
  Alcohol use 
 Family history of ICB  
Social factors Marital status  
Education  
 
Table 2. Clinical and demographic factors potentially associated with PD-ICB 
‘Potentially modifiable’ implies possible avenues for treatment. Withdrawal and reductions in DRT are known to reduce 
PD-ICB risk. While depression, anxiety, smoking and alcohol use are treatable risk factors, evidence is lacking on whether 
treating these features improves outcome in PD-ICB. Symptomatic treatments are available for RBD and apathy but we 
would speculate that the presence of these syndromes represents a PD-phenotype more prone to PD-ICB, rather than a 
modifiable risk factor. 
*Associated with PD-ICB in metanalysis by Liu and colleagues49. 
**Not associated with PD-ICB in metanalysis by Liu and colleagues49. 
 
 
 
  
Management 
Because DA-use is the greatest predictor of PD-ICB, the gold-standard ‘treatment’ is to avoid 
DA in those at greatest risk or to withdraw the medication if PD-ICBs occur. This is reasonable 
as it is increasingly recognised that DAs are less efficacious, have less tolerable side-effects, 
and confer a lower quality-of-life than levodopaS51. The following should be considered: 
• Dopamine-agonist withdrawal syndrome (DAWS), or low mood following dose 
tapering can make it difficult to cease DA treatment19 S52. Some patients may require 
a long-term low dose of DA to prevent apathy or other psychological sequelae. 
• Non-DA therapies including levodopa and possibly even deep-brain stimulation (DBS) 
can cause PD-ICBS53. Though DBS been reported to improve PD-ICBs in most cases, as 
discussed under ‘management’ below. 
• PD-ICB can persistS54 or ‘relapse’29 in syndromal and subsyndromal forms, even after 
withdrawal of DAS54. 
Therefore, other management options are needed to complement or even replace DA-
withdrawal. Appropriate application of these measures requires thorough clinical assessment 
and effective risk stratification of PD-ICBs. 
Clinical assessment 
PD-ICBs are increasingly recognised as a dimensional spectrum of behaviour severity and not 
a categorical diagnosis19 (see figure 1). This has led to the development of clinical assessment 
tools aimed not only at PD-ICB diagnosis but at grading severity according to its psychosocial 
impact. Examples include: 
1. Questionnaire on impulsivity in Parkinson’s- Rating Scale (QUIP-RS)16 
A 28-point patient- or clinician-completed questionnaire. It has been independently 
validated in individuals with advanced PDS55 and used as an outcome measure in 
clinical trialsS15. Like the QUIP screening tool from which it originates, the QUIP-RS is 
highly sensitive but non-specific for diagnostic purposesS56.  
 
2. Ardouin Scale of Behaviour in Parkinson’s Disease (ASBPD)56 
This semi-structured interview evaluates a range of hypo- and hyperdopaminergic 
psychological complications in PD, including PD-ICB. It has been validated and used in 
a clinical trialS57. The clinimetrics for the overall scale were acceptable but the internal 
consistency measures, inter-rater reliability and test-retest reliability for many of the 
ICB-specific assessments were lowS58. It is designed for use by psychiatrists and 
psychologists familiar with PD and takes about an hour to perform, perhaps limiting 
its use in routine practice. 
3. Parkinson’s Impulse Control Scale (PICS)17 
This more recently designed scale uses a semi-structured interview to grade 
behaviours for the full spectrum of PD-ICBs, on the basis of both intensity and impact. 
The semi-structured design complements normal clinical assessment, allowing for 
input from patients, caregivers and clinicians. It can be performed quickly but requires 
an experienced clinician. It likely has a higher sensitivity to detecting DDS compared 
with the QUIP-RS and ASBPD by specifically enquiring about off-period dysphoria. The 
validation study demonstrated excellent inter-rater reliability and fair test-retest 
reliability at 6 months, potentially representing true clinical fluctuations. 
These scales have been subject to two systematic reviews7 S59. Aside from those listed above, 
several more scales exist which apply only to specific ICB subtypes. The QUIP-RS and ASBPD 
met the threshold to be ‘recommended’ in a Movement Disorder Society review for clinical 
use7. The PICS, whilst ‘suggested’, now likely also meets the threshold for ‘recommended’ 
given its more widespread use29. 
While it may be assumed that a higher severity score requires more urgent intervention, there 
is insufficient longitudinal data to correlate present severity score with future risk of 
deterioration. PD-ICB severity can change significantly over relatively short periods of one to 
two years, with risks of both deterioration and relapse29. Further study is warranted to assess 
the use of PD-ICB rating scales in risk stratifying patients to direct management. 
Pharmacological management 
No pharmacological agents are currently licensed for the treatment of PD-ICB. Several agents 
have been trialled with very modest results: 
• In a randomised controlled trial (RCT), Naltrexone did not improve the severity of PD-
ICD measured by clinician rated Clinical Global Impression of Change (CGI) but did 
reduce the severity as measured by the patient-completed QUIP-RSS15. While 
warranting further investigation, a major clinical benefit seems unlikely from these 
results alone. 
• Amantadine is used in the treatment of levodopa-induced dyskinesiaS60. If dyskinesia 
and PD-ICBs represent similar signalling processes in different striatal regions, it could 
be theorised that amantadine may mitigate the impulsive effects of DRT. One small 
placebo-controlled studyS16 and another non-controlled study by the same groupS17 
found amantadine to be beneficial in the treatment of PG in PD. However, the rate of 
adverse effects was high and observational studies appear to indicate that 
amantadine use is actually associated with a greater risk of PD-ICB33 S18. 
• The SSRI citalopramS13 and the SNRI atomoxetineS14 S61 demonstrated improvement in 
psychometric measures of impulsivity in small trials of PD patients, but have not been 
trialled in PD-ICB patients.  
• Other: Evidence on other anti-ICB medications comes only from case reports and 
series. In a systematic review of such cases, sodium valproate demonstrated the most 
consistently positive results S62. 
To date, no pharmacologic agents have sufficient evidence for the treatment of PD-ICB. 
 
Non-pharmacological 
PD patients are already subjected to a high pill-burden and significant adverse effects. 
Therefore, non-pharmacological interventions for non-motor symptoms such as PD-ICBs are 
being increasingly explored. These include: 
• Psychotherapy 
As outlined above, psychosocial determinants are important in the formulation of PD-
ICB. Healthier coping strategies may break the cycle of novelty-seeking and harm-
avoidance, mitigating the behaviours’ impact. One RCT48 found that 28 patients 
receiving immediate CBT demonstrated significantly greater improvement in PD-ICB 
severity measured by CGI and improvements in anxiety and depression levels 
compared to 17 wait-listed controls, who subsequently demonstrated response to 
CBT 6 months later57. Consideration of CBT for PD-ICBs is recommended by the 
National Institute for Health and Care Excellence (NICE) S63. CBT may provide a useful 
adjunct or primary therapy in treating PD-ICB and warrants larger trials58. 
• DBS 
Despite conflicting case reports and seriesS53 on whether STN-DBS has beneficial or 
detrimental effects on PD-ICB, a systematic reviewS64 and prospective observational 
studies with extended follow-up periods59 S65 report an improvement in PD-ICBs in 
most patients. This seemingly contradicts experimental evidence that STN activity is 
inhibitory to impulsivity, and functional inhibition of the STN by DBS should increase 
risky decision makingS66. However, it appears that any such effect is likely superseded 
by the ‘anti-impulsive’ benefits of medication reductionS67. Furthermore, some studies 
found that DBS itself reduces the severity of PD-ICB, independent of medication 
changes60. One longitudinal study found a significant reduction in the prevalence of 
PG and hypersexuality but only a trend towards this effect in CS and an increase in 
punding cases. Certain personality traits also increased risk of persisting or de novo 
PD-ICB. BE has also been reported to persist following STN-DBS59. So STN-DBS may 
have differing effects according to PD-ICB subtype. 
While DBS appears to have beneficial effects for most PD-ICB patients, clinicians 
should be aware of reported cases of existing PD-ICBs worsening, remaining 
unchanged or developing de novoS64. Such cases of DBS-associated PD-ICBs are 
theorised to be due to spread of current from the dorsolateral motor region of the 
STN to the closely associated ventromedial limbic regionS68. Therefore, adjustments in 
electrode configuration to direct the electrical field away from these regions may be 
effective in avoiding or reversing these effectsS69. Patients may also experience a 
transient increase in impulsive behaviours in the acute phase after the insertion of 
electrodes, typically lasting less than a year59. If future guidelines are to suggest DBS 
as a management option for PD-ICB, attention should be given to these mixed results, 
the importance of electrode placement and configuration, and close patient follow-
up. A RCT of STN-DBS in PD-ICB would help to direct such guidance. 
Summary and biopsychosocial model 
PD-ICBs are characterised by subjective loss of control, and exists on a broad spectrum of 
severity. The evidence presented in this review supports the roles of biological, psychological 
and social factors which may predispose patients to PD-ICBs and perpetuate these 
behaviours. 
Figure 2 illustrates a biopsychosocial model of PD-ICB pathophysiology and management. This 
model is by no means definitive as much of the pathophysiology remains unclear. However, 
by combining the most salient findings from neurochemical, imaging, psychological and 
clinical studies creates a clearer picture of PD-ICB formulation. Biological factors such as 
genetic polymorphisms, D2/D3-receptor and DAT availability may predispose certain patients 
to PD-ICB. Other biological changes in dopaminergic circuitry and metabolism have been 
associated with PD-ICB, and some of these changes may predate the introduction of DRT. 
Therefore, these factors may have a role in predisposition and/or perpetuation or may simply 
be biomarkers of PD-ICBs or DRT therapy. The same can goes for psychological comorbidities 
such as apathy, depression and anxiety. 
PD-ICBs can be difficult to manage and evidence on treatments is lacking. This model supports 
a holistic management strategy, combining pharmacological and non-pharmacological 
therapies aimed at reducing the severity of PD-ICBs and improving quality-of-life for patients 
and caregivers. 
Key points: 
• PD-ICBs exists across a broad spectrum of severity, ranging from traits that may be 
considered ‘within normal limits’ to pathological ICD of extreme intensity, occurring 
in 14% to 40% of PD patients. 
• Dysfunction in reward circuits projecting from the VTA to cortical and sub-cortical 
areas, and heterogeneity in dopamine signalling, have been proposed to mediate PD-
ICB. 
• DA-use, DA-LEDD, total LEDD, amantadine use, PD duration, younger age, male sex 
and smoking, amongst other factors, have been associated with greater risk of PD-ICB, 
with genetic risk factors emerging. 
• Subtle differences may exist between PD-ICB subtypes. For instance, in psychological 
profile, clinical risk factors and response to DBS. Such observations warrant replication 
and further investigation. 
• First-line management should include gradual dose reduction and complete 
withdrawal of DAs where possible. Non-pharmacological approaches include 
psychotherapy/CBT and possibly DBS. 
 
  
 
Figure 1. Conceptual illustration of the PD-ICB spectrum 
PD-ICB exist on a spectrum of severity determined by both the frequency of the impulsive activity and the intensity or 
magnitude of that activity. i.e. the impact that it has on patients and caregivers. At the mild end of the spectrum, these 
behaviours may be considered ‘within normal limits’ and have little or no impact. At the severe end of the spectrum, 
behaviours typically meet the diagnostic criteria for PD-ICD.  In the middle of the spectrum however, behaviours may not 
meet these criteria and be considered ‘subsyndromal’, but still have a significant impact that may require monitoring or 
intervention. 
Adapted from PICS rating scale17 and results from Baig and colleagues, 201929
 
Figure 2. Biopsychosocial model of the pathophysiology and management of PD-ICB 
This simplified model summarises the biological, psychological and social mechanisms that may be implicated in the predisposition, precipitation and perpetuation of PD-ICB, and how these factors can be 
targeted in the management of PD-ICB. 
Pathophysiological mechanisms are highlighted in blue. Management options are highlighted in red. 
Dashed arrows signify factors which have been associated with PD-ICB, though the direction of this relationship is unclear. These factors may therefore have a role in predisposition, perpetuation, or neither. 
DAT; Dopamine transporter, DBS; Deep Brain Stimulation, CBT; Cognitive Behavioural therapy, ICB; Impulse control Behaviour, PD; Parkinson’s Disease.
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